You’ve seen many patients face financial hurdles during treatment. Our nonprofit advocacy partners provide alternative savings options to help patients pay for (and move forward with) their treatment plans.
Through collaborations and partnerships with other industry leaders, we’ve dedicated ourselves to fertility advocacy and financial assistance to make a difference in patients’ lives. The following organizations provide loans, grants, or scholarships that can help your patients manage the cost of treatment when growing their family.*
LIVESTRONG helps men and women diagnosed during their reproductive years understand cancer-related risks to fertility. They also provide eligible patients with access to discounted fertility preservation services and free EMD Serono medication.
To empower Black women to take charge of their fertility and reproductive health, Fertility for Colored Girls offers education, awareness, support, and encouragement to Black women, Black couples, and other women of color who are experiencing infertility and seeking to build a family.
The organization also provides grants through yearly fundraisers to support patients going through IVF treatment.
Learn more about Fertility for Colored Girls
RESOLVE promotes reproductive health and equal access to all family-building options for men and women experiencing infertility or other reproductive disorders. They also provide financial guidance for treatment.
The Cade Foundation provides educational programs on pathways to parenthood, as well as grants to help families with the cost of adoption and fertility treatment.
INCIID (pronounced “inside”) helps individuals and couples explore their family-building options. They also provide grants for IVF treatment through a series of yearly fundraising events.
This leader in education and financial assistance helps men start families through gestational surrogacy.
With a focus on creating awareness through support in the fertility community, Baby Quest provides financial assistance through fertility grants to those who cannot afford the high cost of advanced procedures such as IVF, gestational surrogacy, egg and sperm donation, egg freezing, artificial insemination, and embryo donation.
The Bundle of Joy Fund advocates for infertility education and awareness, and offers financial assistance for IVF treatment to those struggling to conceive a child through the REACH Clinic of Charlotte.
HelpCureHD is on a mission to prevent the gene that causes Huntington’s Disease, a hereditary brain disorder, from being passed on to future generations. They provide monetary assistance to close the financial gap that stands between some couples and PGT-M IVF, the only option available that guarantees a biological child is HD-free.
Support doesn’t always have to be financial. We also collaborate with organizations that assist fertility and family-building through other efforts.
An advocate for LGBTQ families and those who wish to form them, Family Equality Council focuses on advancing legal and lived equality by building community, changing hearts and minds, and driving policy change.
Comprised of leading experts in the field, The Alliance is on a mission to increase information, resources, and access to fertility preservation for cancer patients and the healthcare professionals who treat them.
Pregnantish helps people with infertility navigate the emotional, personal, and practical realities of an often-overwhelming process. Their mission is to inspire, educate, and connect the millions of women and men who are starting their families.
*These links are provided solely as a convenience to you and not as an endorsement by EMD Serono of the content on such third-party web sites.
Summary of Contraindications Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU are contraindicated in patients with prior hypersensitivity to rhFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin. Please scroll for full IMPORTANT RISK INFORMATION or see full Prescribing Information for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU. * RFF: Revised Formulation Female
Important Risk Information for Gonal-f® RFF* Redi-ject® (follitropin alfa injection) Contraindications:
Warnings and Precautions:
Adverse Reactions: The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, and ovarian hyperstimulation. The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising). Patient Counseling: In addition to advising patients about the proper use of treatment, the duration and necessity of monitoring, handling of missed doses, OHSS, and multi-fetal gestation and birth, patients should be advised to review the Patient Information Leaflet which contains risk information, follow the Instructions for Use for the Gonal-f® RFF* Redi-ject®, not share the device or reuse needles, and to ask their Healthcare Provider about questions. Indications and Usage:
Prior to treatment complete an evaluation of female and male partners to determine infertility diagnosis and fertility status. Primary ovarian failure and pregnancy should be excluded.
* RFF: Revised Formulation Female
Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection) Contraindications:
WARNINGS Overstimulation of the Ovary During FSH Therapy:
Pulmonary and Vascular Complications
Multiple Births
PRECAUTIONS
Adverse Reactions: Indications and Usage:
Prior to treatment complete an evaluation of female to determine infertility diagnosis and fertility status. Patients with a tubal obstruction should receive Gonal-f® only if enrolled in an in vitro fertilization program. Primary ovarian failure and pregnancy should be excluded. Men
Important Risk Information for Gonal-f® RFF* 75 IU (follitropin alfa for injection) Contraindications:
WARNINGS For use by physicians specializing in fertility treatment or reproductive health and only when appropriate monitoring facilities are available. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis. The lowest effective dose should be used. Overstimulation of the Ovary During FSH Therapy:
Pulmonary and Vascular Complications:
Multiple Births
PRECAUTIONS
Adverse Reactions: The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, ovarian hyperstimulation, breast pain, vaginal hemorrhage, sinusitis, pharyngitis and rhinitis. The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising). Indications and Usage:
Prior to treatment complete an evaluation of female and male partners to determine infertility diagnosis and fertility status. Patients with a tubal obstruction should receive Gonal-f® only if enrolled in an in vitro fertilization program. Primary ovarian failure and pregnancy should be excluded.
* RFF: Revised Formulation Female |
Important Risk Information for Cetrotide® (cetrorelix acetate for injection) Cetrotide® is contraindicated in women who are pregnant, are nursing, or have severe renal impairment. Cetrotide® is also contraindicated in women who exhibit or have known hypersensitivity to cetrorelix acetate, mannitol, extrinsic peptide hormone, GnRH or any other GnRH analogs. Treatment with Cetrotide® is not advised in women with severe allergic conditions. Cases of hypersensitivity reactions, including anaphylactoid reactions have been reported. Other adverse events reported include ovarian hyperstimulation syndrome, nausea, headache, and local injection site reactions. Multiple births and congenital abnormalities have been reported. Indication
|
Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Ovidrel® PreFilled Syringe should only be used by physicians who are experienced with infertility problems, their management and appropriate selection and monitoring of patients. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations, mannitol, or one of their other excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled intracranial lesion, abnormal uterine bleeding of an undetermined origin, an ovarian cyst or enlargement of an undetermined origin. Women who are pregnant or nursing should not use Ovidrel® PreFilled Syringe. Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications. Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported. Indication
|
Summary of Contraindications Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU are contraindicated in patients with prior hypersensitivity to rhFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin. Please scroll for full IMPORTANT RISK INFORMATION or see full Prescribing Information for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU. * RFF: Revised Formulation Female
Important Risk Information for Gonal-f® RFF* Redi-ject® (follitropin alfa injection) Contraindications:
Warnings and Precautions:
Adverse Reactions: The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, and ovarian hyperstimulation. The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising). Patient Counseling: In addition to advising patients about the proper use of treatment, the duration and necessity of monitoring, handling of missed doses, OHSS, and multi-fetal gestation and birth, patients should be advised to review the Patient Information Leaflet which contains risk information, follow the Instructions for Use for the Gonal-f® RFF* Redi-ject®, not share the device or reuse needles, and to ask their Healthcare Provider about questions. Indications and Usage:
Prior to treatment complete an evaluation of female and male partners to determine infertility diagnosis and fertility status. Primary ovarian failure and pregnancy should be excluded.
* RFF: Revised Formulation Female
Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection) Contraindications:
WARNINGS Overstimulation of the Ovary During FSH Therapy:
Pulmonary and Vascular Complications
Multiple Births
PRECAUTIONS
Adverse Reactions: Indications and Usage:
Prior to treatment complete an evaluation of female to determine infertility diagnosis and fertility status. Patients with a tubal obstruction should receive Gonal-f® only if enrolled in an in vitro fertilization program. Primary ovarian failure and pregnancy should be excluded. Men
Important Risk Information for Gonal-f® RFF* 75 IU (follitropin alfa for injection) Contraindications:
WARNINGS For use by physicians specializing in fertility treatment or reproductive health and only when appropriate monitoring facilities are available. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis. The lowest effective dose should be used. Overstimulation of the Ovary During FSH Therapy:
Pulmonary and Vascular Complications:
Multiple Births
PRECAUTIONS
Adverse Reactions: The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, ovarian hyperstimulation, breast pain, vaginal hemorrhage, sinusitis, pharyngitis and rhinitis. The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising). Indications and Usage:
Prior to treatment complete an evaluation of female and male partners to determine infertility diagnosis and fertility status. Patients with a tubal obstruction should receive Gonal-f® only if enrolled in an in vitro fertilization program. Primary ovarian failure and pregnancy should be excluded.
* RFF: Revised Formulation Female |
Important Risk Information for Cetrotide® (cetrorelix acetate for injection) Cetrotide® is contraindicated in women who are pregnant, are nursing, or have severe renal impairment. Cetrotide® is also contraindicated in women who exhibit or have known hypersensitivity to cetrorelix acetate, mannitol, extrinsic peptide hormone, GnRH or any other GnRH analogs. Treatment with Cetrotide® is not advised in women with severe allergic conditions. Cases of hypersensitivity reactions, including anaphylactoid reactions have been reported. Other adverse events reported include ovarian hyperstimulation syndrome, nausea, headache, and local injection site reactions. Multiple births and congenital abnormalities have been reported. Indication
|
Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Ovidrel® PreFilled Syringe should only be used by physicians who are experienced with infertility problems, their management and appropriate selection and monitoring of patients. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations, mannitol, or one of their other excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled intracranial lesion, abnormal uterine bleeding of an undetermined origin, an ovarian cyst or enlargement of an undetermined origin. Women who are pregnant or nursing should not use Ovidrel® PreFilled Syringe. Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications. Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported. Indication
|